Download PDF
Hamostaseologie 1982; 02(01): 24-30
DOI: 10.1055/s-0038-1656561
Originalarbeiten
Schattauer GmbH

Pathophysiologische und experimentelle Grundlagen für die Prophylaxe des plötzlichen Herztodes mit Aggregationshemmern

H. J. Reimers
1   Medizinischen Klinik und Poliklinik, Klinik A, der Universität Düsseldorf (Direktor: Prof. Dr. W. Schneider)
› Author Affiliations
Further Information

Publication History

Publication Date:
21 June 2018 (online)

Also available at
    Permissions and Reprints

 

 

  • LITERATUR

  • 1 Ali M., McDonald J. W. D.. Reversible and irreversible inhibition of platelet cyclooxyge-nase and serotonin release by non-steroidal antiinflammatory drugs. Thrombosis Research 1978; 13: 1057
    CrossrefPubMedGoogle Scholar
  • 2 Andrassy K., Malluche Bornefeld H.. Prevention of p.o. clotting of a.v. cimino fistulae with acetylsalicylic acid. Results of a prospective double blind study. Klin. Wschr. 1974; 52: 348
    CrossrefPubMedGoogle Scholar
  • 3 Au T. L. S., Collins G. A., Harvie C. J., Walker M. J. A.. The actions of prostaglandins I2 and E2 on arrhythmias produced by coronary occlusion in the rat and dog. Prostaglandins 1979; 18: 707
    CrossrefPubMedGoogle Scholar
  • 4 Buchanan M. R., Rosenfeld J., Hirsh J.. The prolonged effect of sulfinpyrazone on collagen-induced platelet aggregation in vivo. Thrombosis Research 1978; 13: 883
    CrossrefPubMedGoogle Scholar
  • 5 Buchanan M. R., Dejana E., Gent M., Mustard J. F., Hirsh J.. Enhanced platelet accumulation onto injured carotid arteries in rabbits after aspirin treatment. J. clin. Invest. 1981; 67: 503
    CrossrefPubMedGoogle Scholar
  • 6 Butler K. D., White A. M.. Inhibition of platelet involvement in the sublethal Forss-man reaction by sulfinpyrazone. In McGregor M., Mustard J. F., Oliver M. F., Sherry S.. (eds.) Cardiovascular actions of sulfinpyrazone: Basic and clinical research. Miami Symposia Specialists, S. 3, 1980
    PubMedGoogle Scholar
  • 7 Cazenave J. P., Packham M. A., Kin-lough-Rathbone R. L., Mustard J. F.. Platelet adherence to the vessel wall and to collagen-coated surfaces. Advances in Experimental Medicine and Biology 1978; 102: 31
    PubMedGoogle Scholar
  • 8 Chandler A. B., Chapman I., Erhardt L. R., Roberts W. C., Schwartz C. J., Sinapius D., Spain D. M., Sherry S., Ness P. M., Simon T. L.. Coronary thrombosis in myocardial infarction. Report of a workshop on the role of coronary thrombosis in the pathogenesis of acute myocardial infarction. Amer. J. Cardiol. 1974; 34: 823
    CrossrefPubMedGoogle Scholar
  • 9 Collins G. A., Johnston K. M., Martinez T. T., Walker M. J. A.. Prostaglandins have limited actions on abnormalities of beating induced in cultured heart cells. Prostaglandins 1979; 18: 591
    CrossrefPubMedGoogle Scholar
  • 10 Cortellaro M., Boschetti C., Fassio G., Basagni M., Polli E. E.. A controlled trial of the effect of sulfinpyrazone on platelet survival and on platelet-bound 14C-serotonin release in patients with previous myocardial infarction. Acta haemat. 1979; 61: 68
    CrossrefPubMedGoogle Scholar
  • 11 Curwen K. D., Gimbrone M. A., Handin R. I.. In vitro studies of thromboresistance: the role of prostacyclin (PGI2) in platelet adhesion to cultured normal and virally transformed human vascular endothelial cells. Lab. Invest. 1980; 42: 366
    PubMedGoogle Scholar
  • 12 Davies J. A., Essien E., Cazenave J. P., Kinlough-Rathbone R. L., Gent M., Mustard J. F.. The influence of red blood cells on the effects of aspirin or sulfinpyrazone on platelet adherence to damaged rabbit aorta. Brit. J. Haemat. 1979; 42: 283
    CrossrefPubMedGoogle Scholar
  • 13 Dejana E., Cazenave J. P., Groves H. M., Kinlough-Rathbone R. L., Richardson M., Packham M. A., Mustard J. F.. The effect of aspirin inhibition of PGI2 production on platelet adherence to normal and damaged rabbit aorta. Thrombosis Research 1980; 17: 453
    CrossrefPubMedGoogle Scholar
  • 14 Di Minno G., Villa S., Bertele De Gaetano V.. Dipyridamole as an antithrombotic agent: an intricate mechanism of action. In Noseda G., Lewis B., Paoletti R.. (eds.) Diet and drugs in atherosclerosis. Raven Press; New York: 1980
    Google Scholar
  • 15 Dix R. K., Kelliher G. J., Jurkiewicz N., Lawrence T. H.. The influence of prostacyclin on coronary occlusion-induced arrhythmia in cats. Prostaglandins and Medicine 1979; 3: 173
    CrossrefPubMedGoogle Scholar
  • 16 Ellis E. F., Wright K. F., Jones P. S., Richardson D. W., Ellis C. K.. Effect of oral aspirin dose on platelet aggregation and vascular prostacyclin (PGI2) synthesis in humans or rabbits. J. Cardiovascular Pharmacology 1980; 2: 387
    PubMedGoogle Scholar
  • 17 Fields W. S., Lemak N. A., Frankowski R. F., Hardy R. J.. Controlled trial of aspirin in cerebral ischemia. Stroke 5/301 1977
    PubMedGoogle Scholar
  • 18 Folts J. E. D., Crowell E. B., Rowe G. G.. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 365
    CrossrefPubMedGoogle Scholar
  • 19 Folts J. E. D., Rowe G. G.. Platelet aggregation in stenosed coronarles: mechanism of sudden death. Amer. J. Cardiol. 1978; 41: 425
    PubMedGoogle Scholar
  • 20 Forfar J. C , Russell D. C., Oliver M. F.. Acute hemodynamic effects of oral sulfinpyrazone on exercise responses in man. Circulation 1980; 62 III 327 Supplementum
    PubMedGoogle Scholar
  • 21 Friedman M., Manwaring J. H., Rosen-man R. H., Donlon G., Ortega P., Grube S. M.. Instantaneous and sudden deaths. Clinical and pathological differentiation in coronary artery disease. J. Amer. med. Ass. 1973; 225: 1319
    CrossrefPubMedGoogle Scholar
  • 22 Goldstein R. E., Davenport N. J., Capur-ro N. L., Lipson L. C., Bonow R. O., Shulman N. R., Epstein S. E.. Relative effects of sulfinpyrazone and Ibuprofen on canine platelet function and prostaglandin-mediated coronary vasodilation. J. Cardiovascular Pharmacology 1980; 2: 399
    PubMedGoogle Scholar
  • 23 Gordon J. L., Pearson J. D.. Effects of sulfinpyrazone and aspirin on prostaglandin I2 (prostacyclin) synthesis by endothelial cells. Brit. J. Pharmacol. 1978; 64: 481
    CrossrefPubMedGoogle Scholar
  • 24 Haerem J. W.. Platelet aggregates inintramyo-cardial vessels of patients dying suddenly and unexpectedly of coronary artery disease. Atheroslerosis 1972; 15: 199
    CrossrefPubMedGoogle Scholar
  • 25 Haerem J. W.. Mural platelet microthrombi and major acute lesions of main epicardial arteries in sudden coronary death. Atherosclerosis 1974; 19: 529
    CrossrefPubMedGoogle Scholar
  • 26 Harker L. A., Ritchie J. L.. The role of platelets in acute vascular events. Circulation 1980; 62 V 13 Supplementum
    PubMedGoogle Scholar
  • 27 Harris W. H., Salzman E. W., Athanasou-lis C. A., Waltmann A. C., De Sanctis R. S.. Aspirin prophylaxis of venous thromboembolism after total hip replacement. New Engl. J. Med. 1977; 297: 1246
    CrossrefPubMedGoogle Scholar
  • 28 Harter H. R., Burch J. W., Majerus P. W., Stanford N., Delmez J. A., Anderson C. B., Weerts C. A.. Prevention of thrombosis in patients on hemodialysis by low dose aspirin. New Engl. J. Med. 1979; 301: 577
    CrossrefPubMedGoogle Scholar
  • 29 Jakobsen P., Kistein Pedersen A.. Two metabolites of sulfinpyrazone and their identification and determination by mass specto-metry. J. Pharmaceutical Pharmacology 1981; 33: 89
    PubMedGoogle Scholar
  • 30 Jobin F.. Acetylsalicylic acid. hemostasis, and human thromboembolism. Seminars in Thrombosis and Haemostasis 1978; 4: 199
    PubMedGoogle Scholar
  • 31 Jorgensen L., Rowsell H. C., Hovig T., Glynn M. F., Mustard J. F.. Adenosine diphos-phate-induced platelet aggregation and myocardial infarction in swine. Lab. Invest. 1967; 17: 616
    PubMedGoogle Scholar
  • 32 Jorgensen L.. Pathophysiologische und experimentelle Hinweise auf die Bedeutung der Thrombozyten bei koronarer Herzkrankheit und plötzlichem Herztod. In Abe T., Sherry S.. (eds.) Ein neuer Weg zur Eindämmung des Herztodes. Huber, Bern, Stuttgart, Wien 1979; S. 27
    PubMedGoogle Scholar
  • 33 Kelton J. G., Hirsh J., Carter C. J., Buchanan M. R.. Thrombogenic effect of high-dose aspirin in rabbits: relationship to inhibition of vessel wall synthesis of prostaglandin I2-like activity. J. Clin. Invest. 1978; 62: 892
    CrossrefPubMedGoogle Scholar
  • 34 Kinlough-Rathbone R. L., Cazenave J. P., Packham M. A., Mustard J. F.. Effect of inhibition of the arachidonate pathway on the release of granule contents from platelets adherent to collagen. Lab. Invest. 1980; 42: 28
    PubMedGoogle Scholar
  • 35 Kuller D.. Sudden death - definition and epidemiologic considerations. Progr. cardio-vasc. Dis. 1980; 23: 1
    CrossrefPubMedGoogle Scholar
  • 36 Lewis G. P., Westwick J.. The effect of sulfinpyrazone. sodium aspirin and Oxprenolol on the formation of arterial platelet thrombi. British Journal of Pharmacology 1975; 55: 255P
    PubMedGoogle Scholar
  • 37 Livio M., Villa S., DeGaetano G.. Long-lasting inhibition of platelet prostaglandin but normal vascular prostacyclin generation following sulfinpyrazone administration to rats. J. Pharmaceutical Pharmacology 1980; 32: 718
    PubMedGoogle Scholar
  • 38 Lovegrove T., Thompson P.. The role of acute myocardial infarction in sudden cardiac death - a statisticians' nightmare. Amer. Heart J. 1978; 96: 711
    CrossrefPubMedGoogle Scholar
  • 39 Maguire E. D., Pay G. F., Turney J., Wallis R. B., Weston M. J., White A. M., Williams L. C., Woods H. F.. The effects of two different dosage regimens of sulfinpyrazone on platelet function ex vivo and blood chemistry in man. Haemostasis 1981; 10: 153
    PubMedGoogle Scholar
  • 40 Maseri A., Chierchia S., L' Abbate A.. Pathogenetic mechanisms underlying the clinical events associated with atherosclerotic heart disease. Circulation 1980; 62: 3 Supplementum V
    PubMedGoogle Scholar
  • 41 Moncada S., Vane J. R.. Prostacyclin in the cardiovascular system. Advances in Prostaglandin and Thromboxane Research 1980; 6: 43
    PubMedGoogle Scholar
  • 42 Moneada S., Korbut R.. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet 1978; I: 1286
    PubMedGoogle Scholar
  • 43 Moschos C. B., Lahirt K., Lyons M., Weisse A. B., Oldenwurtel H. A., Regan T. J.. Relationship of microcirculatory thrombosis to thrombus formation in the proximal coronary artery: effect of aspirin dipyridamol and thrombolysis. Amer. Heart J. 1973; 86: 61
    CrossrefPubMedGoogle Scholar
  • 44 Moschos C. B., Haider B., DeLaCruz Jr. C., Lyons M. M., Regan T. J.. Antiarrhythmic effects of aspirin during nonthrombotic coronary occlusion. Circulation 1978; 57: 681
    CrossrefPubMedGoogle Scholar
  • 45 Moschos C. B.. General Discussion. In: Proceedings of the workshop on platelet active drugs in the secondary prevention of cardiovascular events. Circulation 1980; 62: 122 Supplementum V
    PubMedGoogle Scholar
  • 46 Moschos C. B., Escobinas A. J., Jorgen-sen O. B., Regan T. J.. Effect of sulfinpyrazone on ventricular fibrillation during acute myocardial infarction. Circulation 1981; 64: 13
    CrossrefPubMedGoogle Scholar
  • 47 Mustard J. F.. General Discussion. In: Proceedings of the workshop on platelet active drugs in the secondary prevention of cardiovascular events. Circulation 1980; 62: 47 Supplementum V
    PubMedGoogle Scholar
  • 48 Mustard J. F.. General Discussion. I. Future directions in basic research. In: Proceedings of the workshop on platelet active drugs in the secondary prevention of cardiovascular events. Circulation 1980; 62: 126 Supplementum V
    PubMedGoogle Scholar
  • 49 Needleman P. H., Kaley G.. Cardiac and coronary prostaglandin synthesis and function. New Engl. J. Med. 1978; 298: 1122
    CrossrefPubMedGoogle Scholar
  • 50 Niewiarowski S., Lukasiewicz H., Nath N., Tai Sha A.. Inhibition of human platelet aggregation by dipyridamole and two related compounds and its modification by acid glycoproteins of human plasma. J. Lab. Clin. Med. 1975; 86: 64
    PubMedGoogle Scholar
  • 51 Nowak J., Kaijser L., Wennmalm A.. Cardiac synthesis of prostaglandins from arachidonic acid. Prostaglandins and Medicine 1980; 4: 205
    CrossrefPubMedGoogle Scholar
  • 52 Packham M. A., Mustard J. F.. Pharmacology of platelet affecting drugs. Circulation 1980; 62: 26 Supplementum V
    PubMedGoogle Scholar
  • 53 Pay G. F., Wallis R. B., Zelaschi D.. The effect of sulfinpyrazone and its metabolites on platelet function in vitro and ex vivo. Haemostasis 1981; 10: 165
    PubMedGoogle Scholar
  • 54 Pedersen A. K.. Cardiac prostacyclin release: stimulation by hypoxia and various agents. Scand. J. Haematology, Supplementum 1979; 34: 105
    PubMedGoogle Scholar
  • 55 Pfister B., Godbillon J., Colussi D., Imhof D.. Effect of orally administered sulfinpyrazone (Anturan®) on platelet aggregation in vitro. Thrombosis Research 1980; 18: 89
    CrossrefPubMedGoogle Scholar
  • 56 Preston F. E., Whipps S., Jackson C. A., French A. J., Wyld P. J., Stoddard C. J.. Inhibition of prostacyclin and platelet thromboxane A2 after low dose aspirin. New Engl. J. Med. 1981; 304: 76
    CrossrefPubMedGoogle Scholar
  • 57 Reichenbach D. D., Moss N. S.. Myocardial cell necrosis and sudden death in humans. Circulation 51 1975; 52: 60 Supplementum II
    PubMedGoogle Scholar
  • 58 Roos J. C, Dunning A. J.. Clinical electrophysiological effects of sulfinpyrazone. Circulation 1980; 62: 83 Supplementum III
    PubMedGoogle Scholar
  • 59 Schrör K., Smith III E. F., Bickerton M., Smith J. B., Nicolaou K. C., Magolda R., Lefer A. M.. Preservation of ischemic myocardium by pinane thromboxane A2 . Amer. J. Physiol. 1980; 87
    PubMedGoogle Scholar
  • 60 Schwartz C. J., Gerrity R. G.. Anatomical pathology of sudden unexpected cardiac death. Circulation 1975; 51: 18 52 Supplementum III
    PubMedGoogle Scholar
  • 61 Shragge B. W., Robertson M. A., Nolan W. T., Buchanan M. R., Hirsh J.. The antiarrhythmic effects of sulfinpyrazone in the isolated rabbit heart. Circulation 1980; 62: 83 Supplementum III
    PubMedGoogle Scholar
  • 62 Silver M. G., Hoch W., Kocsis J. J., Ingerman C. M., Smith J. B.. Arachidonic acid causes sudden death in rabbits. Science 1974; 183: 1085
    CrossrefPubMedGoogle Scholar
  • 63 Smith J. B., Araki H., Lefer A. M.. Thromboxane A2 . prostacyclin and aspirin: effects on vascular tone and platelet aggregation. Circulation 1980; 62: 19 Supplementum V
    PubMedGoogle Scholar
  • 64 Smythe H. A., Ogryzlo M. A., Murphey F. A., Mustard J. F.. The effect of sulfinpyrazone (Anturane) on platelet economy and blood coagulation in human. Canad. Med. Ass. J. 1965; 92: 818
    PubMedGoogle Scholar
  • 65 Somberg J. C, Knox S.. The antiarrhythmic action of sulfinpyrazone. Circulation 1980; 62: 82 Supplementum III
    PubMedGoogle Scholar
  • 66 Swift A., Karmazyn M., Horrobin D. F., Manku M. S., Karmali R. A., Morgan R. O., Ally A. I.. Low prostaglandin concentrations cause cardiac rhythm disturbances. Effect reversed by low levels of copper or chloroqui-ne. Prostaglandins 1978; 15: 651
    PubMedGoogle Scholar
  • 67 Trachte G. J., Lefer A. M., Aharony D., Smith J. B.. Potent constriction of cat coronary arteries by hydro-peroxides of arachidonic acid and its blockade by antiinflammatory agents. Prostaglandins 1979; 18: 909
    CrossrefPubMedGoogle Scholar
  • 68 Verstraete M.. Les antiaggregants plaquettai-res. Rev. Prat. (Paris) 1981; 31: 509
    PubMedGoogle Scholar
  • 69 Weksler B. B., Ley C. W., Jaffe E. A.. Stimulation of endothelial cell prostacyclin production by thrombin. trypsin, and the ionophore A 23,187. J. Clin. Invest. 1978; 62: 923
    CrossrefPubMedGoogle Scholar
  • 70 White A. M.. Mögliche Wirkungsmechanismen von Plättchenregulatoren auf der Basis experimenteller Befunde. In Abe T, Sherry S.. Ein neuer Weg zur Eindämmung des Herztodes. Huber, Bern, Stuttgart, Wien 1979; S. 43
    PubMedGoogle Scholar
  • 71 Zimmermann R., Thiessen M., Mörl H., Weckesser G.. The paradoxical thrombogenic effect of aspirin in experimental thrombosis. Thrombosis Research 1979; 16: 843
    CrossrefPubMedGoogle Scholar